Key facts
- Clasp Therapeutics’s last known valuation is $191.5M (Dec 2023).
- It has raised $150.0M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Alexandria Venture Investments, Novo Holdings, Catalio Capital Management, Spur Capital Partners, Vivo Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Clasp Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Clasp Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clasp Therapeutics
Developer of a precision oncology platform designed to support the development of targeted therapies for hard-to-treat cancers. The company's platform identifies tumor-specific neoantigens from oncogenic driver mutations and creates agents that selectively bind to HLA-presented peptides, enabling clinical-stage immuno-oncology firms to develop therapeutics that precisely target and destroy cancer cells across multiple tumor types.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2020
- Employees
- 50
- Website
- clasptx.com/
- Ownership
- Privately Held (backing)
Clasp Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clasp Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clasp Therapeutics in its N-PORT filings yet. We sweep new filings monthly.